[1]
|
Daugherty, S.L., Powers, J.D., Magid, D.J., et al. (2012) Incidence and Prognosis of Resistant Hypertension in Hyper-tensive Patients. Circulation, 125, 1635-1642. https://doi.org/10.1161/CIRCULATIONAHA.111.068064
|
[2]
|
Carey, R.M., Calhoun, D.A., Bakris, G.L., et al. (2018) Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement from the American Heart Association. Hypertension (Dallas, Tex: 1979), 72, E53-E90.
https://doi.org/10.1161/HYP.0000000000000084
|
[3]
|
Acelajado, M.C., Hughes, Z.H., Oparil, S., et al. (2019) Treatment of Resistant and Refractory Hypertension. Circulation Research, 124, 1061-1070. https://doi.org/10.1161/CIRCRESAHA.118.312156
|
[4]
|
Bangalore, S., Fayyad, R., Laskey, R., et al. (2014) Prevalence, Predictors, and Outcomes in Treatment-Resistant Hypertension in Patients with Coronary Disease. The American Journal of Medicine, 127, 71-81.e1.
https://doi.org/10.1016/j.amjmed.2013.07.038
|
[5]
|
Groenland, E.H., Bots, M.L., Asselbergs, F.W., et al. (2021) Apparent Treatment Resistant Hypertension and the Risk of Recurrent Cardiovascular Events and Mortality in Patients with Established Vascular Disease. International Journal of Cardiology, 334, 135-141. https://doi.org/10.1016/j.ijcard.2021.04.047
|
[6]
|
韩魁, 张晨. 难治性高血压诊治的研究进展[J]. 实用心脑肺血管病杂志, 2019, 27(S2): 233-236.
|
[7]
|
邹金兵, 韩津津, 韩丽华. 难治性高血压的定义演变与最新研究进展[J]. 中国医学创新, 2021, 18(8): 175-179.
|
[8]
|
Grassi, G., Mark, A. and Esler, M. (2015) The Sympathetic Nervous Sys-tem Alterations in Human Hypertension. Circulation Research, 116, 976-990. https://doi.org/10.1161/CIRCRESAHA.116.303604
|
[9]
|
孙宁玲, 霍勇, 王继光, 等. 难治性高血压诊断治疗中国专家共识[J]. 中国医学前沿杂志(电子版), 2013, 5(6): 10-17.
|
[10]
|
Zhang, J., Liang, J., Zhang, X., et al. (2021) Non-Invasive Systemic Hemodynamic Index in Vascular Risk Stratification Tailored for Hypertensives. Frontiers in Cardiovascular Medicine, 8, Article ID: 744349.
https://doi.org/10.3389/fcvm.2021.744349
|
[11]
|
Pimenta, E., Gaddam, K.K., Oparil, S., et al. (2009) Effects of Die-tary Sodium Reduction on Blood Pressure in Subjects with Resistant Hypertension: Results from a Randomized Trial. Hypertension (Dallas, Tex: 1979), 54, 475-481.
https://doi.org/10.1161/HYPERTENSIONAHA.109.131235
|
[12]
|
Bloch, M.J. and Basile, J.N. (2010) Combina-tion Angiotensin Receptor Blocker-Neutral Endopeptidase Inhibitor Provides Additive Blood Pressure Reduction over Angiotensin Receptor Blocker Alone. The Journal of Clinical Hypertension (Greenwich), 12, 809-812. https://doi.org/10.1111/j.1751-7176.2010.00358.x
|
[13]
|
Abdin, A., Schulz, M., Riemer, U., et al. (2022) Sacubi-tril/Valsartan in Heart Failure: Efficacy and Safety in and Outside Clinical Trials. ESC Heart Failure, 9, 3737-3750. https://doi.org/10.1002/ehf2.14097
|
[14]
|
Vaduganathan, M., Mentz, R.J., Claggett, B.L., et al. (2023) Sacubi-tril/Valsartan in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Pre-Specified Participant-Level Pooled Analysis of PARAGLIDE-HF and PARAGON-HF. European Heart Journal, 44, 2982-2993. https://doi.org/10.1093/eurheartj/ehad344
|
[15]
|
Gu, J., Noe, A., Chandra, P., et al. (2010) Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi). Journal of Clinical Pharmacology, 50, 401-414.
https://doi.org/10.1177/0091270009343932
|
[16]
|
Mangiafico, S., Costello-Boerrigter, L.C., Andersen, I.A., et al. (2013) Neutral Endopeptidase Inhibition and the Natriuretic Peptide System: An Evolving Strategy in Cardiovascular Therapeutics. European Heart Journal, 34, 886-893.
https://doi.org/10.1093/eurheartj/ehs262
|
[17]
|
Mitchell, G.F., Izzo, J.L., Lacourci, R.E., et al. (2002) Omapatrilat Reduces Pulse Pressure and Proximal Aortic Stiffness in Patients with Systolic Hypertension: Results of the Conduit Hemodynamics of Omapatrilat International Research Study. Circulation, 105, 2955-2961. https://doi.org/10.1161/01.CIR.0000020500.77568.3C
|
[18]
|
Kostis, J.B., Packer, M., Black, H.R., et al. (2004) Omapatrilat and Enalapril in Patients with Hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) Trial. American Journal of Hypertension, 17, 103-111.
https://doi.org/10.1016/j.amjhyper.2003.09.014
|
[19]
|
Ruilope, L.M., Dukat, A.B., et al. (2010) Blood-Pressure Re-duction with LCZ696, a Novel Dual-Acting Inhibitor of the Angiotensin II Receptor and Neprilysin: A Randomised, Double-Blind, Placebo-Controlled, Active Comparator Study. The Lancet (London, England), 375, 1255-1266. https://doi.org/10.1016/S0140-6736(09)61966-8
|
[20]
|
Kario, K., Sun, N., Chiang, F.T., et al. (2014) Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients with Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study. Hypertension (Dallas, Tex: 1979), 63, 698-705. https://doi.org/10.1161/HYPERTENSIONAHA.113.02002
|
[21]
|
Mcmurray, J.J., Packer, M., Desai, A.S., et al. (2014) Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. The New England Journal of Medicine, 371, 993-1004. https://doi.org/10.1056/NEJMoa1409077
|
[22]
|
Kario, K. (2013) Proposal of a New Strategy for Ambu-latory Blood Pressure Profile-Based Management of Resistant Hypertension in the Era of Renal Denervation. Hyperten-sion Research: Official Journal of the Japanese Society of Hypertension, 36, 478-484. https://doi.org/10.1038/hr.2013.19
|
[23]
|
Kario, K., Tamaki, Y., Okino, N., et al. (2016) LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients with Severe Hypertension. Journal of Clinical Hypertension (Greenwich, Conn), 18, 308-314. https://doi.org/10.1111/jch.12667
|
[24]
|
Williams, B., Cockcroft, J.R., Kario, K., et al. (2017) Effects of Sacubitril/Valsartan versus Olmesartan on Central Hemodynamics in the Elderly with Systolic Hypertension: The PARAMETER Study. Hypertension (Dallas, Tex: 1979), 69, 411-420. https://doi.org/10.1161/HYPERTENSIONAHA.116.08556
|
[25]
|
Supasyndh, O., Sun, N., Kario, K., et al. (2017) Long-Term (52-Week) Safety and Efficacy of Sacubitril/Valsartan in Asian Patients with Hypertension. Hypertension Research: Official Journal of the Japanese Society of Hypertension, 40, 472-476. https://doi.org/10.1038/hr.2016.151
|
[26]
|
Wang, J.G., Yukisada, K., Sibulo, A., et al. (2017) Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Add-On to Amlodipine in Asian Patients with Systolic Hypertension Uncontrolled with Amlodipine Monotherapy. Journal of Hypertension, 35, 877-885. https://doi.org/10.1097/HJH.0000000000001219
|
[27]
|
Almarjan, A.I., Almarjan, S.A. and Masoud, A.T. (2023) Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis. High Blood Pressure & Cardiovascular Prevention: The Official Journal of the Italian Soci-ety of Hypertension, 30, 207-218.
https://doi.org/10.1007/s40292-023-00572-7
|
[28]
|
Packer, M., Mcmurray, J.J., Desai, A.S., et al. (2015) Angioten-sin Receptor Neprilysin Inhibition Compared with Enalapril on the Risk of Clinical Progression in Surviving Patients with Heart Failure. Circulation, 131, 54-61.
https://doi.org/10.1161/CIRCULATIONAHA.114.013748
|
[29]
|
Jackson, A.M., Jhund, P.S., Anand, I.S., et al. (2021) Sacubitril-Valsartan as a Treatment for Apparent Resistant Hypertension in Patients with Heart Failure and Pre-served Ejection Fraction. European Heart Journal, 42, 3741-3752.
https://doi.org/10.1093/eurheartj/ehab499
|
[30]
|
Li, W., Gong, M., Yu, Q., et al. (2022) Efficacy of Angiotensin Re-ceptor Neprilysin Inhibitor in Asian Patients with Refractory Hypertension. Journal of Clinical Hypertension (Greenwich, Conn), 24, 449-456.
https://doi.org/10.1111/jch.14454
|
[31]
|
Kusaka, H., Sueta, D., Koibuchi, N., et al. (2015) LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More than Valsartan Alone. American Journal of Hypertension, 28, 1409-1417. https://doi.org/10.1093/ajh/hpv015
|
[32]
|
Li, X., Braza, J., Mende, U., et al. (2021) Cardioprotective Effects of Early Intervention with Sacubitril/Valsartan on Pres-sure Overloaded Rat Hearts. Scientific Reports, 11, Article No. 16542.
https://doi.org/10.1038/s41598-021-95988-3
|
[33]
|
Shi, Y.J., Yang, C.G., Qiao, W.B., et al. (2023) Sacubi-tril/Valsartan Attenuates Myocardial Inflammation, Hypertrophy, and Fibrosis in Rats with Heart Failure with Preserved Ejection Fraction. European Journal of Pharmacology, 961, Article ID: 176170. https://doi.org/10.1016/j.ejphar.2023.176170
|
[34]
|
Chen, J., Pei, Y., Wang, Q., et al. (2023) Effect of Sacubi-tril/Valsartan or Valsartan on Ventricular Remodeling and Myocardial Fibrosis in Perimenopausal Women with Hyper-tension. Journal of Hypertension, 41, 1077-1083.
https://doi.org/10.1097/HJH.0000000000003430
|
[35]
|
Lyu, T.J., Liu, Y., Zhang, H., et al. (2022) Clinical Observa-tion of Sacubitril Valsartan Sodium in the Treatment of Resistant Hypertension: A Randomized Clinical Trial. Frontiers in Cardiovascular Medicine, 9, Article ID: 1099043.
https://doi.org/10.3389/fcvm.2022.1099043
|
[36]
|
Wang, B., Wang, G.H., Ding, X.X., et al. (2022) Effects of Sacu-bitril/Valsartan on Resistant Hypertension and Myocardial Work in Hemodialysis Patients. Journal of Clinical Hyperten-sion (Greenwich, Conn), 24, 300-308.
https://doi.org/10.1111/jch.14422
|